MedTrace Logo

Synergistic Effect of Vedolizumab and Pentoxifylline

NCT02953275 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-07-11

No results posted yet for this study

Summary

The purpose of this study is to determine the synergistic effect and clinical benefits of vedolizumab and pentoxifylline in the management of patients with inflammatory bowel disease.

Conditions

  • Crohn Disease

Interventions

DRUG

vedolizumab

standard of care

DRUG

Pentoxifylline

added to vedolizumab

DRUG

placebo

added to vedolizumab

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Amar R Deshpande, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-13
Primary Completion
2019-03-18
Completion
2019-06-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02953275 on ClinicalTrials.gov